title: Effects of Ecklonia cava polyphenol in individuals with hypercholesterolemia: a pilot study.
abstract: We evaluated the efficacy and safety of Ecklonia cava polyphenol (Seapolynol™, a polyphenol antioxidant and anti-inflammatory agent purified from E. cava) during a 12-week treatment period (400 mg orally once daily) in individuals with hypercholesterolemia and performed subgroup analysis for metabolic syndrome (MetS). As a noncomparative study, forty-six individuals (M:F=22:24, mean age=54±11 years) with fasting total cholesterol concentration >240 mg/dL or low-density lipoprotein cholesterol (LDL-C) concentration >130 mg/dL were enrolled. Hip circumference (100±7 cm vs. 98±7 cm, P<.01), total cholesterol (244±25 mg/dL vs. 225±37 mg/dL, P<.01), LDL-C (161±24 mg/dL vs. 146±34 mg/dL, P<.01), and C-reactive protein (2.51±3.55 mg/L vs. 1.37±1.32 mg/L, P<.05) were significantly decreased without significant adverse effect. A differential assessment according to the presence [MetS(+) group, n=18] and absence [MetS(-) group, n=28] of MetS showed that Hb(A1c) decreased significantly following 12-week Seapolynol treatment in the MetS(+) compared with the MetS(-) group (-0.3%±0.5% vs. 0.1%±0.3%, P<.01). In conclusion, although our results showed that Seapolynol treatment is effective and safe without significant adverse events or abnormal laboratory findings during a 12-week period in individuals with hypercholesterolemia, more research in a larger population with a longer-term follow-up period in a randomized placebo-controlled study is needed to confirm the results.
authors.affiliation: Division of Cardiology, Department of Internal Medicine, The Catholic University of Korea, Uijeongbu St. Mary's Hospital, Uijeongbu, Republic of Korea.
authors.forename: Dong Hyeon
authors.initials: DH
authors.lastname: Lee
authors.forename: Mi Yeon
authors.initials: MY
authors.lastname: Park
authors.forename: Byung Joo
authors.initials: BJ
authors.lastname: Shim
authors.forename: Ho Joong
authors.initials: HJ
authors.lastname: Youn
authors.forename: Hye Jeong
authors.initials: HJ
authors.lastname: Hwang
authors.forename: Hyeon Cheol
authors.initials: HC
authors.lastname: Shin
authors.forename: Hui Kyung
authors.initials: HK
authors.lastname: Jeon
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000886:Anthropometry; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D044466:Asian People; D002097:C-Reactive Protein / Q000032:analysis / Q000378:metabolism; D008078:Cholesterol, LDL / Q000097:blood; D005215:Fasting / Q000097:blood; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D008297:Male; D024821:Metabolic Syndrome / Q000150:complications / Q000188:drug therapy; D008875:Middle Aged; D000459:Phaeophyceae / Q000737:chemistry*; D010865:Pilot Projects; D059808:Polyphenols / Q000032:analysis* / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood; D055815:Young Adult
chemical_list: D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; D059808:Polyphenols; D014280:Triglycerides; D002097:C-Reactive Protein